KR20150082606A - 겜시타빈 전구약물 및 그의 용도 - Google Patents

겜시타빈 전구약물 및 그의 용도 Download PDF

Info

Publication number
KR20150082606A
KR20150082606A KR1020157015453A KR20157015453A KR20150082606A KR 20150082606 A KR20150082606 A KR 20150082606A KR 1020157015453 A KR1020157015453 A KR 1020157015453A KR 20157015453 A KR20157015453 A KR 20157015453A KR 20150082606 A KR20150082606 A KR 20150082606A
Authority
KR
South Korea
Prior art keywords
group
oxo
cancer
anilino
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157015453A
Other languages
English (en)
Korean (ko)
Inventor
로렌스 아이. 우
Original Assignee
보옌 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보옌 테라퓨틱스, 인크. filed Critical 보옌 테라퓨틱스, 인크.
Publication of KR20150082606A publication Critical patent/KR20150082606A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020157015453A 2012-11-13 2013-11-12 겜시타빈 전구약물 및 그의 용도 Ceased KR20150082606A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725643P 2012-11-13 2012-11-13
US61/725,643 2012-11-13
PCT/US2013/069640 WO2014078295A1 (en) 2012-11-13 2013-11-12 Gemcitabine prodrugs and uses thereof

Publications (1)

Publication Number Publication Date
KR20150082606A true KR20150082606A (ko) 2015-07-15

Family

ID=50681903

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157015453A Ceased KR20150082606A (ko) 2012-11-13 2013-11-12 겜시타빈 전구약물 및 그의 용도

Country Status (10)

Country Link
US (3) US8956613B2 (enExample)
EP (1) EP2919790B1 (enExample)
JP (1) JP6420247B2 (enExample)
KR (1) KR20150082606A (enExample)
CN (1) CN104968353B (enExample)
AU (1) AU2013345007B2 (enExample)
BR (1) BR112015010941A2 (enExample)
CA (1) CA2891124A1 (enExample)
SG (1) SG11201503773SA (enExample)
WO (1) WO2014078295A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078295A1 (en) 2012-11-13 2014-05-22 BoYen Therapeutics, Inc. Gemcitabine prodrugs and uses thereof
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016078397A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物及其应用
WO2016078399A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物二聚体及其应用
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
WO2016078163A1 (zh) 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物二聚体及其应用
ITUB20159671A1 (it) * 2015-12-22 2017-06-22 Maurizio Ceruti Carbammati lipidici di farmaci antitumorali
PT3393478T (pt) * 2015-12-23 2020-03-24 NuCana plc Terapia combinada
CN106946960A (zh) * 2017-03-29 2017-07-14 郑州泰基鸿诺医药股份有限公司 一种吉西他滨前药的晶型、制备方法、用途和药物组合物
CA3061621A1 (en) 2017-04-26 2018-11-01 Thomas I. Kalman Multitargeted nucleoside derivatives
CN108329371B (zh) * 2018-03-06 2021-04-09 沈阳药科大学 白蛋白结合型吉西他滨前药及其合成和应用
JP7598313B2 (ja) * 2018-04-26 2024-12-11 ナノメッド ホールディングス プロプライエタリー リミテッド ジェムシタビン両親媒性プロドラッグ
GR1009958B (el) * 2019-04-24 2021-03-18 ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." Παραγωγα γεμσιταβινης και μεθοδοι δημιουργιας παραγωγων γεμσιταβινης
GB201906214D0 (en) 2019-05-02 2019-06-19 Econic Tech Ltd A polyol block copolymer, compositions and processes therefor
GB201906210D0 (en) 2019-05-02 2019-06-19 Econic Tech Limited A polyol block copolymer, compositions and processes therefor
CN114011581B (zh) * 2021-11-09 2023-03-24 昆明理工大学 一种弱酸性条件下铜硫分离的抑制剂制备方法及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994558A (en) 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
US4814438A (en) 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
ATE236188T1 (de) * 1997-01-24 2003-04-15 Conpharma As Gemcitabin-derivate
GB2321454A (en) 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0321613D0 (en) 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
FR2874016B1 (fr) 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
WO2006029081A2 (en) 2004-09-02 2006-03-16 Neopharm, Inc. Nucleoside-lipid conjugates, their method of preparation and uses thereof
WO2006030217A2 (en) 2004-09-15 2006-03-23 Drug Discovery Laboratory As Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
US7691827B2 (en) 2004-12-17 2010-04-06 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof
NO322682B1 (no) 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
AT502221A1 (de) 2005-07-20 2007-02-15 Pharmacon Forschung & Beratung Gmbh Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
WO2007149891A2 (en) 2006-06-21 2007-12-27 Eli Lilly And Company Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
CN101209350B (zh) 2006-12-30 2011-09-07 中国人民解放军军事医学科学院毒物药物研究所 以氨基酸为连接子的多聚谷氨酸-药物偶合物
WO2010039039A1 (en) 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives
JP2012505228A (ja) 2008-10-07 2012-03-01 レクサン ファーマシューティカルズ インコーポレイテッド Ｈｐｍａ−ドセタキセルまたはゲムシタビンコンジュゲートおよびその使用
CN101525361B (zh) 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
US8871780B2 (en) 2009-07-02 2014-10-28 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, method of making and use thereof
JP2013511516A (ja) 2009-11-20 2013-04-04 クラヴィス・ファルマ・アーエスアー ゲムシタビン誘導体の非経口製剤
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012098557A1 (en) 2011-01-20 2012-07-26 Institute Of Life Sciences Pegylated gemcitabine derivative and process for preparing the same
EP2739290A4 (en) 2011-08-02 2015-04-15 Clovis Oncology Inc METHOD FOR SELECTION OF CHEMOTHERAPEUTICS AGAINST ADENOCARCINOMAS
CN102432654A (zh) 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
WO2014078295A1 (en) 2012-11-13 2014-05-22 BoYen Therapeutics, Inc. Gemcitabine prodrugs and uses thereof
CN103130854A (zh) 2013-01-31 2013-06-05 华东师范大学 维生素e琥珀酸酯化吉西他滨前药及应用

Also Published As

Publication number Publication date
US20150132298A1 (en) 2015-05-14
EP2919790B1 (en) 2018-04-04
AU2013345007B2 (en) 2018-08-30
CN104968353B (zh) 2017-12-22
SG11201503773SA (en) 2015-06-29
US20140134160A1 (en) 2014-05-15
EP2919790A4 (en) 2016-04-06
CA2891124A1 (en) 2014-05-22
WO2014078295A1 (en) 2014-05-22
CN104968353A (zh) 2015-10-07
US9890189B2 (en) 2018-02-13
WO2014078295A8 (en) 2015-05-21
JP6420247B2 (ja) 2018-11-07
EP2919790A1 (en) 2015-09-23
AU2013345007A1 (en) 2015-05-21
JP2016503414A (ja) 2016-02-04
US9540410B2 (en) 2017-01-10
US20170107245A1 (en) 2017-04-20
BR112015010941A2 (pt) 2017-07-11
US8956613B2 (en) 2015-02-17

Similar Documents

Publication Publication Date Title
KR20150082606A (ko) 겜시타빈 전구약물 및 그의 용도
JP7414525B2 (ja) クロファラビンのプロドラッグ
US20080090842A1 (en) Novel pyridyl cyanoguanidine compounds
KR102810546B1 (ko) 암의 치료를 위한 4'-티오-뉴클레오타이드 및 -뉴클레오사이드 전구약물
JP2015537008A (ja) ピラゾロピリミジン化合物
KR20080039508A (ko) 인데노이소퀴놀리논 유사체 및 이의 사용 방법
EP1838696B1 (en) Novel cyanoguanidine compounds
US11701377B2 (en) Methods for treating cancers by prodrugs of clofarabine
CA3042671C (en) Prodrugs of clofarabine
JP2022535849A (ja) チアラビンベースおよびチアラビンのプロドラッグベースの治療
CN101146774A (zh) 4-去甲基五氯甲定的衍生物、其用途及其制备
AU2002308264A1 (en) Novel pyridyl cyanoguanidine compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150610

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181109

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200206

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200710

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200206

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I